ClinicalTrials.gg
CompletedNCT01143389Updated Jun 6, 2018Results posted

Corneal Crosslinking in Patients With Keratoconus and Post-Refractive Ectasia

A Phase 2 interventional study of Riboflavin and UVX light in Keratoconus and Post-Refractive Ectasia, sponsored by Price Vision Group. Completed at 1 site in United States. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2018-06-06.

Sponsored by Price Vision Group · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
510
Allocation
Randomized
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing riboflavin in Keratoconus — 5 open to participants now, 8 under way, 7 of them phase 3. Riboflavin · Keratoconus.

Enrollment
3rd of 23
510 · median 170
Started
2010
with 5 others
Phase 2
3 of 23
none open now
Registered
4th of 23
by date
Lead sponsor
3 of 23
Price Vision Group

Among the 23 studies testing riboflavin in Keratoconus, this one is the 3rd largest by enrollment, is one of 6 that started in 2010, is one of 3 in phase 2, and was the 4th registered.

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

Browse Keratoconus studies →

Open to participants now

5 of the 23 studies testing riboflavin in Keratoconus are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

About riboflavin

Riboflavin: first FDA approval 1953 (M.V.I.-12 ADULT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 10 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing riboflavin in Keratoconus, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness of using riboflavin and UV light to treat progressive keratoconus or post-refractive corneal ectasia.

Read the detailed description

The primary objective of this study is to evaluate two riboflavin-dosing regimens for corneal collagen cross-linking to slow the progressive changes in corneal curvature in eyes with progressive keratoconus or post-refractive ectasia.

03

Conditions studied

  • Keratoconus
  • Post-Refractive Ectasia

Keywords

  • Keratoconus
  • Ectasia
  • cross linking
  • collagen cross linking
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 10 years of age or older
  2. Having documented ectasia on topography or tomography after previous refractive surgery OR progressive keratoconus defined as one or more of the following changes over a period of 36 months or less before randomization:

    1. An increase of ≥ 1.00 D in the steepest keratometry value (or sim K)
    2. An increase of ≥ 1.00 D in regular astigmatism evaluated by subjective manifest refraction
    3. A myopic shift (decrease in the spherical equivalent) of ≥ 0.50 D on subjective manifest refraction
    4. Documented decrease in visual acuity associated with irregular astigmatism and topographic features of ectasia.
  3. Subjects with keratoconus diagnosis only:

    a. Axial topography consistent with keratoconus b. Presence of central or inferior steepening on the Pentacam map. c. Presence of one or more slit lamp findings associated with keratoconus, such as: i. Fleischer ring ii. Vogt striae iii. Corneal thinning iv. Corneal scarring

  4. Contact Lens Wearers Only: Removal of contact lenses for the required period of time prior to the screening refraction:

    Contact Lens Type Minimum Discontinuation Time Soft 3 Days Soft Extended Wear 1 Week Soft Toric 2 Weeks Rigid gas permeable 2 Weeks

  5. Signed written

Exclusion criteria

Exclusion Criteria:

    1. Any keratoconus patient over 21 years of age without evidence of progression of his corneal deformity.

      1. Patients with excessively thin corneas. 3. Previous ocular condition in the eyes to be treated that may predispose the eye for future complications, for example:

      a. History of corneal disease (e.g., herpes simplex, herpes zoster keratitis, recurrent erosion syndrome, corneal melt, corneal dystrophy, etc.) b. corneal scarring in the proposed treatment zone 4. A history of chemical injury or delayed epithelial healing in the eye(s) to be treated.

      1. A known sensitivity to treatment medications. 6. Patients with a current condition that, in the treating physician's opinion, would interfere with or prolong epithelial healing.
      1. Pregnancy (including plan to become pregnant) or lactation during the course of the study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
510 participants (actual)

Study arms

  • Active comparator
    Riboflavin 0.1% eyedrops every 5 minutes

    The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 5 minutes for this arm).

    Drug: Riboflavin · Device: UVX light

  • Active comparator
    Riboflavin 0.1% eyedrops every 2 minutes

    The eye will be irradiated for 30 minutes with UVX light, during which time instillation of riboflavin will continue (1 drop every 2 minutes for this arm).

    Drug: Riboflavin · Device: UVX light

Interventions

  • Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.

  • DeviceUVX light

    UVX 365 nm wavelength light source is applied with continued application of riboflavin.

06

What researchers measure

Primary outcomes

  1. Change in Maximum Keratometry From Baseline to 6 Months After Treatment

    Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.

    Time frame: 6 months

Secondary outcomes

  1. Pachymetry

    Minimum corneal thickness measured by corneal tomography

    Time frame: 6 months

  2. Corrected Distance Visual Acuity (CDVA)

    Corrected distance visual acuity (CDVA) reported in logarithm of the minimum angle of resolution (logMAR). Lower numbers represent better vision; 0.0 corresponds to 20/20 vision. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.

    Time frame: 6 months

  3. Uncorrected Distance Visual Acuity (UDVA)

    Uncorrected distance visual acuity reported in logarithm of the minimum angle of resolution units. Lower numbers represent better vision; 0.0 corresponds to 20/20 vision without any type of correction such as glasses. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.

    Time frame: 6 months

07

Results

Posted May 4, 2018
Limitations and caveats
Limitations included the 6-month follow up duration and the reduced reproducibility of measurement techniques in eyes with ectasia as compared with normal eyes.

Participant flow

Participant flow — Overall Study
MilestoneRiboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 Minutes
Started253257
Completed227232
Not completed2625
Withdrew: Lost to follow-up2625

Outcome measures

PrimaryChange in Maximum Keratometry From Baseline to 6 Months After Treatment

Change in maximum keratometry (Kmax) between baseline and 6 months after treatment, measured by corneal tomography.

Time frame:
6 months
Reported as:
Mean · diopters
Change in Maximum Keratometry From Baseline to 6 Months After Treatment
dioptersRiboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 Minutes
Change in Maximum Keratometry From Baseline to 6 Months After Treatment0.76 ± 2.40.97 ± 3.2
SecondaryPachymetry

Minimum corneal thickness measured by corneal tomography

Time frame:
6 months
Reported as:
Mean · microns
Pachymetry
micronsRiboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 Minutes
Pachymetry438 ± 51434 ± 20
SecondaryCorrected Distance Visual Acuity (CDVA)

Corrected distance visual acuity (CDVA) reported in logarithm of the minimum angle of resolution (logMAR). Lower numbers represent better vision; 0.0 corresponds to 20/20 vision. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.

Time frame:
6 months
Reported as:
Mean · logMAR
Corrected Distance Visual Acuity (CDVA)
logMARRiboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 Minutes
Corrected Distance Visual Acuity (CDVA)0.32 ± 0.290.31 ± 0.28
SecondaryUncorrected Distance Visual Acuity (UDVA)

Uncorrected distance visual acuity reported in logarithm of the minimum angle of resolution units. Lower numbers represent better vision; 0.0 corresponds to 20/20 vision without any type of correction such as glasses. Each increase of 0.1 on the logMAR scale corresponds to one less line read on the eye chart.

Time frame:
6 months
Reported as:
Mean · logMAR
Uncorrected Distance Visual Acuity (UDVA)
logMARRiboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 Minutes
Uncorrected Distance Visual Acuity (UDVA)0.95 ± 0.530.91 ± 0.55

Adverse events

Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Riboflavin 0.1% Eyedrops Every 5 Minutes0/253 (0%)0/253 (0%)12/253 (4.7%)
Riboflavin 0.1% Eyedrops Every 2 Minutes0/257 (0%)0/257 (0%)13/257 (5.1%)
Most frequent other events
Most frequent other events
EventRiboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 Minutes
Loss of 2 or more logMAR lines of corrected distance visual acuity (CDVA) relative to baselineEye disorders12/25313/257

Baseline characteristics

Age, Continuous
Age, Continuous(years)Riboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 MinutesTotal
Mean32 ± 1232 ± 1332 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)Riboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 MinutesTotal
Female6261123
Male191196387
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Riboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 MinutesTotal
American Indian or Alaska Native000
Asian101323
Native Hawaiian or Other Pacific Islander000
Black or African American282452
White215220435
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Riboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 MinutesTotal
United States253257510
Keratoconus/ectasia classification
Keratoconus/ectasia classification(Participants)Riboflavin 0.1% Eyedrops Every 5 MinutesRiboflavin 0.1% Eyedrops Every 2 MinutesTotal
Keratoconus mild (flat K <51D and astigmatism <8D)140139279
Keratoconus moderate434386
Keratoconus severe (flat K >56D by tomography)202141
Ectasia after refractive surgery5054104
08

Study locations

1 site
  • Price Vision Group
    Indianapolis, Indiana 46260, United States
09

References and documents

Publications

  • Wittig-Silva C, Whiting M, Lamoureux E, Lindsay RG, Sullivan LJ, Snibson GR. A randomized controlled trial of corneal collagen cross-linking in progressive keratoconus: preliminary results. J Refract Surg. 2008 Sep;24(7):S720-5. doi: 10.3928/1081597X-20080901-15. PubMed 18811118 ↗
  • Raiskup-Wolf F, Hoyer A, Spoerl E, Pillunat LE. Collagen crosslinking with riboflavin and ultraviolet-A light in keratoconus: long-term results. J Cataract Refract Surg. 2008 May;34(5):796-801. doi: 10.1016/j.jcrs.2007.12.039. PubMed 18471635 ↗
  • Mazzotta C, Traversi C, Baiocchi S, Sergio P, Caporossi T, Caporossi A. Conservative treatment of keratoconus by riboflavin-uva-induced cross-linking of corneal collagen: qualitative investigation. Eur J Ophthalmol. 2006 Jul-Aug;16(4):530-5. doi: 10.1177/112067210601600405. PubMed 16952090 ↗
  • Caporossi A, Baiocchi S, Mazzotta C, Traversi C, Caporossi T. Parasurgical therapy for keratoconus by riboflavin-ultraviolet type A rays induced cross-linking of corneal collagen: preliminary refractive results in an Italian study. J Cataract Refract Surg. 2006 May;32(5):837-45. doi: 10.1016/j.jcrs.2006.01.091. PubMed 16765803 ↗
  • Price MO, Fairchild K, Feng MT, Price FW Jr. Prospective Randomized Trial of Corneal Cross-linking Riboflavin Dosing Frequencies for Treatment of Keratoconus and Corneal Ectasia. Ophthalmology. 2018 Apr;125(4):505-511. doi: 10.1016/j.ophtha.2017.10.034. Epub 2017 Dec 2. PubMed 29203068 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of May 2017 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in May 2018, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2010
First posted
Jun 14, 2010
Start
May 2010
Primary completionActual
May 30, 2017
CompletionActual
Aug 30, 2017
Results first posted
May 4, 2018
Last update
Jun 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01143389
Lead sponsor
Price Vision Group
Responsible party
Sponsor
First posted
Jun 14, 2010
Start date
May 2010
Primary completion
May 30, 2017
Completion
Aug 30, 2017
Results posted
May 4, 2018
Last update
Jun 6, 2018

Study contacts

Francis W Price, MD
principal investigator · Price Vision Group

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Riboflavin

Start the discussion